KPC Pharmaceuticals (SHA:600422) saw its net profit decline to 390.5 million yuan in the nine months ended Sept. 30 from 396.2 million yuan a year prior, parent China Resources Pharmaceutical Group (HKG:3320) said in an Oct. 25 bourse filing.
The drugmaker's revenue for the period fell to 5.46 billion yuan from 5.61 billion yuan in the year-ago period.
Shares of KPC Pharmaceuticals closed over 6% higher on Monday.
Price (HKD): $15.45, Change: $+0.94, Percent Change: +6.48%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。